Thermo Fisher Scientific (TMO) Investor Day 2024 summary

Strategic vision, positioning, and market outlook

• Focus on enabling customer success through innovation, productivity, and trusted partnerships across life sciences, diagnostics, and applied markets.

• Maintains industry leadership with $42.3B in revenue and over 120,000 employees, serving fast-growing end markets such as pharma, biotech, diagnostics, and advanced materials.

• End markets estimated at $235B, with long-term growth projected at 4-6%, driven by demographics, scientific advances, and increased healthcare demand.

• China remains a long-term growth market, with stimulus expected to drive demand in 2025 and beyond, though below historical highs.

• PPI Business System and CSR strategy drive operational excellence and competitive advantage.

Growth strategy, innovation, and business execution

• Proven growth strategy centers on high-impact innovation, trusted partner status, and an unparalleled commercial engine with global reach and digital capabilities.

• Organic growth target of 7-9% in normal market conditions, consistently outpacing 4-6% underlying market growth.

• Invests ~$1.3B annually in R&D, with 7,200 scientists and a robust innovation pipeline enabling advances in proteomics, genomics, and advanced materials.

• Recent acquisitions (PPD, The Binding Site, Olink) have expanded capabilities in clinical research, diagnostics, and proteomics, delivering strong integration and synergy realization.

• PPI Business System underpins operational excellence, continuous improvement, and successful M&A integration.

Financial performance, capital deployment, and outlook

• Achieved 13% revenue CAGR, 15% EPS CAGR, and 14% adjusted free cash flow CAGR from 2013–2023.

• 2024 guidance: $42.4–$43.3B revenue, (1%)-1% core organic revenue growth, 22.5–22.8% adjusted operating margin, $21.29–$22.07 adjusted EPS.

• 83% of revenue is recurring, supporting stability and resilience.

• Capital deployment prioritizes high-ROI organic investments, disciplined M&A (60–75% of capital), share buybacks, and a growing dividend.

• Long-term outlook: 7–9% organic revenue growth, 40–50 bps annual margin expansion, and mid-teens adjusted EPS and free cash flow growth.